Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Clinical Characteristics, Genomic Profiling and Outcomes of Langerhans Cell Histiocytosis in Adults with Single System Multifocal Disease

Hong-Xiao Han, Long Chang, Min Lang, Lin He, Jian Li, Minghui Duan, Daobin Zhou, Xinxin Cao, Wen Gao

Blood (2023) 142 (Supplement 1): 1165.

https://doi.org/10.1182/blood-2023-178177

Published: 2023

Journal Articles

Adult Langerhans Cell Histiocytosis with Liver Involvement

Long Chang, Lin He, Huacong Cai, Minghui Duan, Jian Li, Daobin Zhou, Gaurav Goyal, Xinxin Cao

Blood (2023) 142 (Supplement 1): 3197.

https://doi.org/10.1182/blood-2023-184790

Published: 2023

Journal Articles

Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenström's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results

Blood (2023) 142 (Supplement 1): 3039.

https://doi.org/10.1182/blood-2023-181500

Published: 2023

Journal Articles

Rituximab Plus Bortezomib for Refractory and Relapsed Warm Autoimmune Hemolytic Anemia：a Prospective, Single-Arm, Phase Ⅱ Trial

Xijuan Lin, Chen Yang, Junling Zhuang, Daobin Zhou, Miao Chen, Bing Han

Blood (2023) 142 (Supplement 1): 3829.

https://doi.org/10.1182/blood-2023-178625

Published: 2023

Journal Articles

C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up

Blood (2023) 142 (Supplement 1): 1025.

https://doi.org/10.1182/blood-2023-182817

Published: 2023

Journal Articles

Lenalidomide and Dexamethasone for Patients with Rosai-Dorfman Disease: A Single Arm, Single Center, Prospective Phase 2 Study

Long Chang, Lin He, Jian Li, Daobin Zhou, Xinxin Cao, Wen Gao

Blood (2023) 142 (Supplement 1): 6331.

https://doi.org/10.1182/blood-2023-184621

Published: 2023

Journal Articles

A Multicenter, Phase III Study of Chidamide, Azacitidine Combined with CHOP Versus CHOP in Patients with Untreated Peripheral T-Cell Lymphoma

Chong Wei, Yan Zhang, Jian Li, Wei Zhang, Daobin Zhou

Blood (2022) 140 (Supplement 1): 6567–6568.

https://doi.org/10.1182/blood-2022-157899

Published: 2022

Journal Articles

Phase Ib/II Study of Rituximab, Lenalidomide and Methotrexate Followed By Lenalidomide Maintenance in Patients with Newly Diagnosed Primary CNS Lymphoma: The Remla Trial

Yan Zhang, Wei Wang, Jian Li, Daobin Zhou, Wei Zhang, Danqing Zhao, Chong Wei, Lu Zhang, Xinxin Cao

Blood (2022) 140 (Supplement 1): 6608–6609.

https://doi.org/10.1182/blood-2022-165934

Published: 2022

Journal Articles

Efficacy and Safety of Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Patients with Mayo 2004 Stage 3 Light-Chain Amyloidosis: A Prospective Phase 2 Study

Ya-Juan Gao, Kaini Shen, Long Chang, Jun Feng, Yueying Mao, Lu Zhang, Xinxin Cao, Daobin Zhou, Jian Li

Blood (2022) 140 (Supplement 1): 4391–4392.

https://doi.org/10.1182/blood-2022-157044

Published: 2022

Journal Articles

Single-Cell Transcriptome Analysis Reveals Stem Cell-like Subsets in the Progression of Waldenström's Macroglobulinemia

Yu Qiu, Xiaoshuang Wang, Yuan Yao, Yanmin Si, Xuezhu Wang, Mingnan Jia, Daobin Zhou, Jia Yu, Jian Li, Xin-xin Cao

Blood (2022) 140 (Supplement 1): 6385–6386.

https://doi.org/10.1182/blood-2022-156435

Published: 2022

Journal Articles

Myc Translocation Is an Adverse Factor Redefining High-Risk Multiple Myeloma

Xianghong Jin, Jianhua Du, Fujing Zhang, Hui Li, Shuangjiao Liu, Chen Yang, Miao Chen, Daobin Zhou, Junling Zhuang

Blood (2022) 140 (Supplement 1): 12575.

https://doi.org/10.1182/blood-2022-169332

Published: 2022

Journal Articles

Efficacy and Safety of Peginterferon Alfa-2b in 95 Patients with Myeloproliferative Neoplasms:a Single Center Retrospective Analysis

Long Chang, Hao Cai, Xinxin Cao, Jian Li, Daobin Zhou, Minghui Duan

Blood (2022) 140 (Supplement 1): 12244.

https://doi.org/10.1182/blood-2022-168360

Published: 2022

Journal Articles

Long-Term Outcomes of Second-Line Vs Later-Line Zanubrutinib Treatment in Patients with Relapsed/Refractory MCL: An Updated Pooled Analysis

Blood (2022) 140 (Supplement 1): 6501–6503.

https://doi.org/10.1182/blood-2022-162135

Published: 2022

Journal Articles

Efficacy and Safety of Orelabrutinib in Relapsed/Refractory Waldenstrom's Macroglobulinemia Patients

Blood (2021) 138 (Supplement 1): 46.

https://doi.org/10.1182/blood-2021-149350

Published: 2021

Journal Articles

The Interim Analysis from a Prospective Single-Center Phase 2 Study of Zanubrutinib Plus R-CHOP in Treat-Naïve Intravascular Large B Cell Lymphoma

Yan Zhang, Congwei Jia, Wei Wang, Lu Zhang, Xinxin Cao, Jian Li, Wei Zhang, Daobin Zhou

Blood (2021) 138 (Supplement 1): 3563.

https://doi.org/10.1182/blood-2021-152417

Published: 2021

Journal Articles

Updated Phase 1 Results of C-CAR088, an Anti-BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 1830.

https://doi.org/10.1182/blood-2021-150037

Published: 2021

Journal Articles

Preliminary Results of Zanubrutinib-Containing Regimens in DLBCL and Cerebrospinal Fluid Distribution of Zanubrutinib

Yan Zhang, Yanan Li, Zhe Zhuang, Wei Wang, Chong Wei, Danqing Zhao, Jian Li, Daobin Zhou

Blood (2021) 138 (Supplement 1): 4556.

https://doi.org/10.1182/blood-2021-150949

Published: 2021

Journal Articles

Relmacabtagene Autoleucel CD19 CART Therapy for Adults with Heavily-Pretreated Relapsed/Refractory Large B-Cell Lymphoma in China

Yuqin Song, Zhitao Ying, Haiyan Yang, Ye Guo, Wenyu Li, Dehui Zou, Daobin Zhou, Zhao Wang, Mingzhi Zhang, Jianqiu Wu, Hui Liu, Pian Zhang, Su Yang, Zisong Zhou, Hongxia Zheng, Jun Zhu

Blood (2021) 138 (Supplement 1): 3557.

https://doi.org/10.1182/blood-2021-148358

Published: 2021

Journal Articles

Clinical Response of CD19 CAR-T Cells (relmacabtagene autoleucel, relma-cel) in Adults with Heavily-Pre-Treated Relapsed/Refractory (r/r) Large B-Cell Lymphoma in China

Jun Zhu, MD, Zhitao Ying, MD, Yuqin Song, MD PhD, Haiyan Yang, MD PhD, Ye Guo, MD, Wenyu Li, PhD, Dehui Zou, MD, Daobin Zhou, MD PhD, Zhao Wang, MD, Mingzhi Zhang, MD, Jianqiu Wu, MD, Hui Liu, MD, Pian Zhang, Su Yang, Zisong Zhou, Hongxia Zheng, MD PhD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-136038

Published: 2020

Journal Articles

Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies

Yuqin Song, MD PhD, Wei Xu, MD PhD, Yongping Song, MD, Lihong Liu, MD, Song Lin, Zhiming Li, MD PhD, Ting Liu, MD PhD, Shuhua Yi, MD, Daobin Zhou, MD PhD, Mingzhi Zhang, MD, Yu Hu, MD, Jie Jin, MD PhD, Huaqiang Zhu, MD, Zhengguang Lu, Renbin Zhao, PhD, Zhixin Xu, MD PhD, Jun Zhu, BS

Blood (2020) 136 (Supplement 1): 43.

https://doi.org/10.1182/blood-2020-140172

Published: 2020

NARROW

Clinical Characteristics, Genomic Profiling and Outcomes of Langerhans Cell Histiocytosis in Adults with Single System Multifocal Disease

Adult Langerhans Cell Histiocytosis with Liver Involvement

Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenström's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results

Rituximab Plus Bortezomib for Refractory and Relapsed Warm Autoimmune Hemolytic Anemia：a Prospective, Single-Arm, Phase Ⅱ Trial

C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up

Lenalidomide and Dexamethasone for Patients with Rosai-Dorfman Disease: A Single Arm, Single Center, Prospective Phase 2 Study

A Multicenter, Phase III Study of Chidamide, Azacitidine Combined with CHOP Versus CHOP in Patients with Untreated Peripheral T-Cell Lymphoma

Phase Ib/II Study of Rituximab, Lenalidomide and Methotrexate Followed By Lenalidomide Maintenance in Patients with Newly Diagnosed Primary CNS Lymphoma: The Remla Trial

Efficacy and Safety of Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Patients with Mayo 2004 Stage 3 Light-Chain Amyloidosis: A Prospective Phase 2 Study

Single-Cell Transcriptome Analysis Reveals Stem Cell-like Subsets in the Progression of Waldenström's Macroglobulinemia

Myc Translocation Is an Adverse Factor Redefining High-Risk Multiple Myeloma

Efficacy and Safety of Peginterferon Alfa-2b in 95 Patients with Myeloproliferative Neoplasms:a Single Center Retrospective Analysis

Long-Term Outcomes of Second-Line Vs Later-Line Zanubrutinib Treatment in Patients with Relapsed/Refractory MCL: An Updated Pooled Analysis

Efficacy and Safety of Orelabrutinib in Relapsed/Refractory Waldenstrom's Macroglobulinemia Patients

The Interim Analysis from a Prospective Single-Center Phase 2 Study of Zanubrutinib Plus R-CHOP in Treat-Naïve Intravascular Large B Cell Lymphoma

Updated Phase 1 Results of C-CAR088, an Anti-BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma

Preliminary Results of Zanubrutinib-Containing Regimens in DLBCL and Cerebrospinal Fluid Distribution of Zanubrutinib

Relmacabtagene Autoleucel CD19 CART Therapy for Adults with Heavily-Pretreated Relapsed/Refractory Large B-Cell Lymphoma in China

Clinical Response of CD19 CAR-T Cells (relmacabtagene autoleucel, relma-cel) in Adults with Heavily-Pre-Treated Relapsed/Refractory (r/r) Large B-Cell Lymphoma in China

Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only